Compare · JNJ vs MRVI
JNJ vs MRVI
Side-by-side comparison of Johnson & Johnson (JNJ) and Maravai LifeSciences Holdings Inc. (MRVI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and MRVI operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $558.86B, about 429.5x MRVI ($1.30B).
- Over the past year, JNJ is up 49.6% and MRVI is up 121.6% - MRVI leads by 72.0 points.
- MRVI has been more active in the news (14 items in the past 4 weeks vs 8 for JNJ).
- JNJ has more recent analyst coverage (25 ratings vs 22 for MRVI).
- Company
- Johnson & Johnson
- Maravai LifeSciences Holdings Inc.
- Price
- $232.15-0.24%
- $5.03+0.30%
- Market cap
- $558.86B
- $1.30B
- 1M return
- +4.36%
- +27.66%
- 1Y return
- +49.56%
- +121.59%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 8
- 14
- Recent ratings
- 25
- 22
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in three segments: Nucleic Acid Production, Biologics Safety Testing, and Protein Detection. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The Protein Detection segment sells labeling and detection reagents for researchers in immunohistochemistry, immunofluorescence, and glycobiology. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.
Latest JNJ
- Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
- Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
- Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
- RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
- New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
- FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
- Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
- SEC Form SD filed by Johnson & Johnson
- SEC Form 13F-HR filed by Johnson & Johnson
- CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense Research
Latest MRVI
- Maravai LifeSciences Holdings Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement, Regulation FD Disclosure
- Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032
- Maravai LifeSciences Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Amendment: Director Lucier Gregory T was granted 46,293 shares, increasing direct ownership by 30% to 201,416 units (SEC Form 4)
- Director Marker Luke Joseph was granted 46,293 shares, increasing direct ownership by 34% to 184,348 units (SEC Form 4)
- Director Gray Susannah was granted 46,293 shares, increasing direct ownership by 27% to 216,200 units (SEC Form 4)
- Director Mihas Constantine S was granted 46,293 shares, increasing direct ownership by 34% to 184,348 units (SEC Form 4)
- Director Eckert R Andrew was granted 46,293 shares, increasing direct ownership by 13% to 412,183 units (SEC Form 4)
- Director Lucier Gregory T was granted 46,293 shares, increasing direct ownership by 30% to 201,416 units (SEC Form 4)
- Director Cunningham Sean Laurence was granted 46,293 shares, increasing direct ownership by 34% to 184,348 units (SEC Form 4)